MP-453087-1 INITIAL COMMERCIAL EXPERIENCE OF A SINGLE-CHAMBER HELIX-FIXATION LEADLESS PACEMAKER

Approximately 1 in 6 conventional, transvenous pacemaker patients experience complications the first 3 years of implant. The Aveir™ VR (Abbott, Abbott Park, IL) is a newly released, single-chamber, ventricular leadless (LP), featuring helix-based fixation mechanism and pre-fixation exploratory electrical mapping capability. By eliminating lead subcutaneous pocket, this alternative to pacemakers may mitigate some related while streamlining implant procedure. Evaluate initial, multi-center commercial Aveir LP. Patients implanted with an device after release United States were consecutively included evaluation. Implant procedural characteristics evaluated, parameters measured, any acute procedure-related noted. centers (N=94, 59% male) LP per standard practice (see representative workflow figure). median [interquartile range] total procedure duration was 36.0 [20.0-90.0] min, fluoroscopy 6.0 [4.1-10.3] min. For 79/94 patient subpopulation procedures limited (e.g., not concurrent extraction, ablation, etc.), 23.0 [19.0-33.0] 5.5 [4.0-9.0] Leveraging capability (1 site mapped 67% patients, 2 sites 27%, 3-5 6%), post-fixation repositioning that could increase risk clinical avoided 94% all patients. LPs low septum (87%), mid (10%), apex (3%) right ventricle. Pacing capture threshold @ 0.4 ms, R-wave amplitude, pacing impedance 0.8 [0.5-1.3] V, 9.5 [7.5-12.0] mV, 750 [560-960] Ω. Acute 99% patients; intraprocedural retrieval occurred address acutely elevated threshold. real-world demonstrated safe efficient implantation minimal repositioning, viable metrics, complications.